8. Falkson, C. I., Ibrahim, J., Kirkwood, J., Coates, A. S., Atkins, M. B.,
and Blum, R. Phase III trial of dacarbazine versus dacarbazine with
interferon 2b versus dacarbazine with tamoxifen versus dacarbazine
with interferon 2b and tamoxifen in patients with metastatic malignant
melanoma: an Eastern Cooperative Oncology Group study (E3690).
J. Clin. Oncol., 16: 1743–1751, 1998.
9. Kirkwood, J. M. Studies of interferon in the therapy of melanoma.
Semin. Oncol., 18 (Suppl. 7): 83– 89, 1991.
10. Sparano, J. A., and Dutcher, J. P. Interleukin-2 for the treatment of
advanced melanoma. Hematol. Oncol. Ann., 1: 279 –285, 1993.
11. Atkins, M. B., Lotze, M., Dutcher, J. P., Fisher, R. I., Weiss, G.,
Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M.,
Paradise, C., Kunkel, L., and Rosenberg, S. A. High dose recombinant
interleukin-2 therapy for patients with metastatic melanoma: analysis of
270 patients treated from 1985–1993. J. Clin. Oncol., 17: 2105–2116,
1999.
12. Sparano, J. A., Fisher, R. I., Sunderland, M., Margolin, K., Ernest,
M. L., Sznol, M., Atkins, M. B., Dutcher, J. P., Micetich, K. C., and
Weiss, G. R. Randomized phase III trial of treatment with high-dose
interleukin-2 either alone or in combination with interferon α-2a in
patients with advanced melanoma. J. Clin. Oncol., 11: 1969 –1977,
1993.
13. Richards, J. M., Gale, D., Mehta, N., and Lestingi, T. Combination
of chemotherapy with interleukin-2 and interferon α for the treatment of
metastatic melanoma. J. Clin. Oncol., 17: 651– 657, 1999.
14. Legha, S. S., and Buzaid, A. C. Role of recombinant interleukin-2
in combination with interferon-α and chemotherapy in the treatment of
advanced melanoma. Semin. Oncol., 2 (Suppl. 9): 27–32, 1993.
15. Atkins, M. B., O'Boyle, K. R., Sosman, J. A., Weiss, G. R.,
Margolin, K. A., Ernest, M. L., Mier, J. W., Sparano, J. A., and Fisher,
R. I. Multi-institutional Phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J. Clin. Oncol., 12: 1553–
1560, 1994.
16. Khayat, D., Borel, C., Tourani, J. M., Benhammouda, A., Antoine,
E., Rixe, O., Viullemin, E., Bazex, P. A., Thill, L., and Franks, R.
Sequential chemoimmunotherapy with cisplatin, interleukin-2 and in-terferon α-2a for metastatic melanoma. J. Clin. Oncol., 12: 2173–2180,
1993.
17. Legha, S. S., Ring, S., Eton, O., Bedikian, A., Buzaid, A. C., Plager,
C., and Papadopoulos, N. Development of a biochemotherapy regimen
with concurrent administration of cisplatin, vinblastine, dacarbazine,
interferon α and interleukin-2 for patients with metastatic melanoma.
J. Clin. Oncol., 16: 1752–1759, 1998.
18. Kaplan, E., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457– 481, 1958.
19. Parkinson, D. R. Interleukin-2 in cancer therapy. Semin. Oncol., 15
(Suppl. 6): 10 –26, 1988.
20. Margolin, K. A., Rayner, A. A., Hawkins, M. J., Atkins, M. B.,
Dutcher, J. P., Fisher, R. I., Weiss, G. R., Doroshow, J. H., Jaffe, H. S.,
and Roper, M. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.
J. Clin. Oncol., 7: 486 – 498, 1989.
21. Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson,
D. R., and Louie, A. C. Results of treatment of 255 patients with
metastatic renal cell carcinoma who received high-dose recombinant
interleukin-2 therapy. J. Clin. Oncol., 13: 688 – 696, 1995.
22. Mitchell, M. S. Relapse in the central nervous system in melanoma
patients successfully treated with biomodulators. J. Clin. Oncol., 7:
1701–1709, 1989.
23. Summers, Y., Middleton, M. R., Calvert, H., Lee, S. M., Rustin, G.,
Newell, D. R., and Thatcher N. Effect of temozolomide on central
nervous system relapse in patients with advanced melanoma. Proc. Am.
Soc. Clin. Oncol., 18: 2048, 1999.
24. Bleehen, N. M., Newlands, S. M., Lee, S. M., Thatcher, L. N.,
Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., and Stevens,
M. F. Cancer research campaign phase II trial of temozolomide in
metastatic melanoma. J. Clin. Oncol., 13: 910 –913, 1995.
